PNEUMOCYSTIS JIROVECII PNEUMONIA IN CHILDREN. RETROSPECTIVE STUDY IN A SINGLE CENTRE ALONG THREE DECADES

Author(s):  
Jorge García Moreno
2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e22088-e22088
Author(s):  
Timothy Dudley Clay ◽  
Ciara Daly ◽  
Philip Craven ◽  
Nisha Sikotra ◽  
Sowmya Cheruvu ◽  
...  

2020 ◽  
Vol 54 (2) ◽  
pp. 221-226
Author(s):  
Petra Rogina ◽  
Miha Skvarc

AbstractBackgroundPneumocystis jirovecii pneumonia (PCP) is a common and potentially fatal opportunistic infection in immunocompromised non-HIV individuals. There are problems with clinical and diagnostic protocols for PCP that lack sensitivity and specificity. We designed a retrospective study to compared several methods that were used in diagnostics of PCP.Patients and methodsOne hundred and eight immunocompromised individuals with typical clinical picture for PCP and suspicious radiological findings were included in the study. Serum samples were taken to measure the values of (1→3)-β-D-glucan (Fungitell, Associates of Cape Cod, USA). Lower respiratory tract samples were obtained to perform direct immunofluorescence (DIF, MERIFLUOR® Pneumocystis, Meridian, USA) stain and real-time PCR (qPCR).ResultsFifty-four (50%) of the 108 patients in our study had (1→3)-β-D-glucan > 500 pg/ml. Patients that had (1→3)-β-D-glucan concentrations < 400 pg/ml in serum, had mean threshold cycles (Ct) 35.43 ± 3.32 versus those that had (1→3)-β-D-glucan concentrations >400 pg/mL and mean Ct of 28.97 ± 5.27 (P < 0.001). If we detected P. jirovecii with DIF and qPCR than PCP was proven. If the concentration of (1→3)-β-D-glucan was higher than 400 pg/ml and Ct of qPCR was below 28.97 ± 5.27 than we have been able be certain that P. jirovecii caused pneumonia (odds ratio [OR] 2.31, 95% confidence interval [CI] 1.62–3.27, P < 0.001).ConclusionsMeasurement of (1→3)-β-D-glucan or qPCR alone could not be used to diagnose PCP. Diagnostic cut-off value for (1→3)-β-D-glucan > 400pg/ml and qPCR below 30 Ct, allow us to conclude that patient has PCP. If the values of (1→3)-β-D-glucan are < 400 pg/ml and qPCR is above 35 Ct than colonization with P. jirovecii is more possible than PCP.


Author(s):  
Jorge García-Moreno ◽  
Susana Melendo-Pérez ◽  
María Teresa Martín-Gómez ◽  
Marie Antoinette Frick ◽  
Joan Balcells-Ramírez ◽  
...  

Author(s):  
Michael Saccente ◽  
Gayathri Krishnan

Abstract In this retrospective study, (1-&gt;3)-β-D-glucan (B-glucan) was an unreliable marker for AIDS-related Pneumocystis jirovecii pneumonia (PCP) because a high percentage of participants with progressive disseminated histoplasmosis and respiratory symptoms had a positive B-glucan result. Where histoplasmosis is common attributing B-glucan positivity to PCP without further testing risks misdiagnosis.


2020 ◽  
Vol 9 (11) ◽  
pp. 3573
Author(s):  
José Ignacio Fortea ◽  
Antonio Cuadrado ◽  
Ángela Puente ◽  
Paloma Álvarez Fernández ◽  
Patricia Huelin ◽  
...  

In liver transplant (LT) recipients, Pneumocystis jirovecii pneumonia (PJP) is most frequently reported before 1992 when immunosuppressive regimens were more intense. It is uncertain whether universal PJP prophylaxis is still applicable in the contemporary LT setting. We aimed to examine the incidence of PJP in LT recipients followed at our institution where routine prophylaxis has never been practiced and to define the prophylaxis strategies currently employed among LT units in Spain. All LT performed from 1990 to October 2019 were retrospectively reviewed and Spanish LT units were queried via email to specify their current prophylaxis strategy. During the study period, 662 LT procedures were carried out on 610 patients. Five cases of PJP were identified, with only one occurring within the first 6 months. The cumulative incidence and incidence rate were 0.82% and 0.99 cases per 1000 person transplant years. All LT units responded, the majority of which provide prophylaxis (80%). Duration of prophylaxis, however, varied significantly. The low incidence of PJP in our unprophylaxed cohort, with most cases occurring beyond the usual recommended period of prophylaxis, questions a one-size-fits-all approach to PJP prophylaxis. A significant heterogeneity in prophylaxis strategies exists among Spanish LT centres.


2020 ◽  
Vol 38 (3) ◽  
pp. 111-118 ◽  
Author(s):  
Jorge García-Moreno ◽  
Susana Melendo-Pérez ◽  
María Teresa Martín-Gómez ◽  
Marie Antoinette Frick ◽  
Joan Balcells-Ramírez ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document